AbInitio Bio
<!-- hacklab:yc-profile -- YC company profile The Intelligence layer for Drug Manufacturing Abinitio Bio builds foundation models for biomanufacturing, validated against wet lab…
About AbInitio Bio
YC company profile
The Intelligence layer for Drug Manufacturing
Abinitio Bio builds foundation models for biomanufacturing, validated against wet lab data. Our first model, Echo, predicts manufacturing outcomes more accurately than standard models, and any pharma or CDMO can adapt it to their own workflow instantly. By making process decisions that take 6-18 months today in hours, we help teams avoid the cost of delay on a single program.
- YC batch: Spring 2026
- Founded: 2026
- Team size: 2
- Location: Boston
- Country: US
- Status: Active
- Industry: Healthcare
- Stage: Early
- YC partner: Nicolas Dessaigne
Founders
Daniel Mukasa — Founder/CEO
Founder & CEO at AbInitio Bio (YC P26). Postdoctoral Fellow at MIT focused on AI and drug discovery. Previously AI/ML intern at Merck working on antibody therapeutic design. PhD in Applied Physics and Materials Science from Caltech.
Nisha Gopal — Founder
Founder CSO at Abinitio Bio (YC P26). Biochemist with 14 years of experience, Stanford PhD, former research scientist at the The Broad Institute of Harvard and MIT
Source: Y Combinator · Retrieved 2026-11-02. Company information is self-reported on YC.